Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases

Seminars in Arthritis and Rheumatism

Volumn 12, Issue 4, 1983, Pages 359-372

  Kovarsky, Joel ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; 4 OXOCYCLOPHOSPHAMIDE; ACROLEIN; ALDOPHOSPHAMIDE; ALLOPURINOL; CHLORAMBUCIL; CHLOROQUINE; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; MESNA; PHOSPHORAMIDE MUSTARD; PREDNISOLONE;

ADVERSE DRUG REACTION; ALOPECIA; BLADDER; BLADDER CANCER; BLOOD AND HEMOPOIETIC SYSTEM; BONE MARROW DEPRESSION; CARCINOGENESIS; CARDIOTOXICITY; CHEMICAL CARCINOGENESIS; CHEMICAL TERATOGENESIS; DRUG ABSORPTION; DRUG ELIMINATION; DRUG INTERACTION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOXICITY; GONAD ATROPHY; HEART; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTOXICATION; JOINT; LUNG TOXICITY; PERIPHERAL VASCULAR SYSTEM; PHARMACOKINETICS; PHARMACOLOGY; PHOSPHAMIDE DERIVATIVE; REPRODUCTIVE TOXICITY; RESPIRATORY SYSTEM; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SKIN TOXICITY; TERATOGENESIS; THERAPY; VASCULITIS;

ABNORMALITIES, DRUG-INDUCED; ALOPECIA; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; CYCLOPHOSPHAMIDE; DRUG INTERACTIONS; ENDOCRINE DISEASES; GONADS; HEMATOLOGIC DISEASES; HUMAN; LUNG DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MYOCARDIAL DISEASES; NEOPLASMS; RHEUMATIC DISEASES; UROLOGIC DISEASES;

EID: 0020962068     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/0049-0172(83)90016-1     Document Type: Article

References (228)

1. Cytostats with effects in chronic inflammation
2. Immunosuppressive therapy in rheumatic disease
3. Versuche uber die Haltbarkeit von Sublimatlosungen
4. Drugs used in cancer chemotherapy
5. Treatment of rheumatoid arthritis with nitrogen mustard Preliminary report
6. Synthese und Abbau cytostatisch wirksamer cyclischer N-Phosphamidester des Bis-(Bchlorathyl)-amins
7. Long term cyclophosphamide therapy in rheumatoid arthritis
8. Immunosuppressive therapy in rheumatoid arthritis
9. Disease-modifying drugs for progressive rheumatoid arthritis
10. Immunosuppressive agents in lupus nephritis: A critical analysis
11. Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis
12. Cyclophosphamide and related phosphoramide mustards: Current status and future prospects
13. Clinical pharmacology of cyclophosphamide
14. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy
15. The quantitation of cyclophosphamide in human blood and urine by mass spectrometry-stable isotope dilution
16. The effect of phenobarbitol on cyclophosphamide anti-tumor activity
17. Effect of microsomal enzyme modifiers on toxicity and therapeutic activity of cyclophosphamide in mice
18. The effect of phenobarbitol or 2-diethyl-aminoethyl-2, 2-diphenylvalerate on the activation of cyclophosphamide in vivo
19. Therapeutic efficacy of cyclophosphamide as a function of its metabolism
20. Preparation of Nphosphorylated derivatives of bis-B-chlorethylamine
21. Neuartige KrebsChemotherapeutika aus der Gruppe der zyklischen N-Lost-Phosphamidester
22. Erst Erfahrungen in der Behandlung maligner Tumoren mit einem neuen N-Lost-Phosphamidester
23. The clinical pharmacology of antineoplastic agents (second of two parts)
24. Zur pharmakologischen Charakterisierung zyklischer N-Lost-Phosphamideste rals Krebs-Chemotherapeutica
25. Studies on the mechanism of action of cytoxan. I. Evidence of activation in vivo
26. Uber de Aktivierung von Cyclophosphamid in vivo und in vitro
27. Enzymatic basis of cyclophosphamide activation by hepatic microsomes in the rat
28. Studies on the mechanisms of action of cytoxan: Evidence of activation in vivo and in vitro
29. Alkylating properties of phosphoramide mustard
30. Primary evaluation of alkylating agent-cyclohexylamine salt of N, N-bis (2-chlorethyl) phosphorodiamidic acid (NSC-69945; OMF-59) in experimental antitumor assay systems
31. Formation of the cytotoxic aldehyde acrolein during in vitro degradation of cyclophosphamide
32. Bioassay and relative cytotoxic potency of cyclophosphamide metabolites generated in vitro and in vivo
33. Uber Beziehugen zwischen chemischer konstitution und cancerotoxischer Wirkung in der Reihe de Phosphamidester de Bis(B-chlorathyl)-amins
34. Identification of phosphoramidic acid mustard as a human metabolite of cyclophosphamide
35. Studies of some newer phosphoramide mustards
36. Urinary metabolites of the antitumor agent cyclophosphamide
37. Metabolism of cyclophosphamide by sheep
38. Pharmacokinetics of cyclophosphamide in renal failure
39. Cyclophosphamide dose in renal failure (letter)
40. Hemodialysis in cancer chemotherapy
41. Comparative effects of cyclophosphamide, isophosphamide, 4-methylcyclophosphamide and phosphoramide mustard on murine hematopoietic and immunocompetent cells
42. Some (pharmacological) properties of chloracetaldehyde, an oxidation product and potential metabolite of cyclophosphamide
43. Timely appraisal: Estopic (extracellular) nucleic acid as a drug target, especially in rheumatoid arthritis and certain cancers (?)
44. Antineoplastic and Immunosuppressive Agents
45. The effect of cyclophosphamide on the immune response
46. Clinical infections, antibiotics and immunosuppression: A puzzling relationship (editorial)
47. Selective depletion of lymphoid tissue by cyclophosphamide
48. 51Cr
49. Differential effects of cyclophosphamide on the B and T cell compartments of adult mice
50. Effect of immunosuppressive drugs on T and B lymphocytes in guinea pigs
51. The effect of cyclophosphamide on leukocyte kinetics and susceptibility to infection in patients with Wegener's granulomatosis
52. Specific acquired immune unresponsiveness to contact allergens with cyclophosphamide in the mouse
53. Prolongation of homograft survival in mice with single doses of cyclophosphamide
54. The effect of cytotoxic drugs on graft versus host disease in mice
55. Tolerance to polyinosinc-polycytidylic acid in NZB/NZW mice
56. Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig
57. Functional aspects of the selective depletion of lymphoid tissue by cyclophosphamide
58. Influence of cyclophosphamide on the delayed hypersensitivity of the mouse
59. Potentiation of T-cell-mediated immunity by selective suppression of antibody formation with cyclophosphamide
60. Influence of cyclophosphamide on delayed hypersensitivity and acquired cellular resistance to Listeria monocytogenes in the mouse
61. Cyclophosphamide-sensitive T-lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T-lymphocytes
62. Differential cyclophosphamide sensitivity of suppressor and cytotoxic cell precursors
63. Selective depletion of Ig-bearing lymphocytes by cyclophosphamide depletion in rheumatoid arthritis and systemic lupus erythematosus: Guidelines for dosage
64. Activation of human B lymphocytes XII. Differential effects of in vitro cyclophosphamide on human lymphocyte subpopulations involved in B cell activation
65. 19S and 7S antibody production in the cyclophosphamide or methotrexate treated rat
66. Immunosuppression by alkylating agents-tolerance induction
67. Studies on the induction of immunological paralysis to bovine globulin in adult mice: II. The effect of cyclophosphamide
68. On the mechanism of immunological tolerance in cyclophosphamide-treated mice
69. Further studies on B-lymphocyte suppression in delayed hypersensitivity, indicating a possible mechanism for Jones-Mote hypersensitivity
70. Enhancing effect of low dose cyclophosphamide on the in vitro antibody response
71. The effect of cyclophosphamide on B and T lymphocytes in patients with connective tissue diseases
72. Effects of cyclophosphamide on B- and T-lymphocytes in rheumatoid arthritis
73. Inhibition of the local inflammatory response in man by antimetabolites
74. Induction in vitro of reversible immunosuppression and inhibition of B cell receptor regeneration by defined metabolites of cyclophosphamide
75. T-suppressor cells sensitive to cyclophosphamide and to its in vitro active derivative 4-hydroperoxycyclophosphamide control the mitogenic response of murine splenic B cells to dextran sulfate. A direct proof for different sensitivities of lymphocyte subsets to cyclophosphamide
76. Relative susceptibilities of T cell subsets involved in delayed-type hypersensitivity to sheep red blood cells to the in vitro action of 4-hydroperoxycyclophosphamide
77. Direct in vitro evidence for different susceptibilities to 4-hydroperoxycyclophosphamide of antigen-primed T cells regulating humoral and cell-mediated immune responses to sheep erythrocytes: A possible explanation for the inverse action of cyclophosphamide on humoral and cell-mediated immune responses
78. In vitro effects of 4-hydroperoxycyclophosphamide on human immunoregulatory T subset function. I. Selective effects on lymphocyte function in T-B cell collaboration
79. Intensive cyclophosphamide (NSC-26271) therapy for solid tumors
80. Effects of cyclophosphamide and of busulfan on spleen colony-forming units and on hematopoietic stroma
81. HLA-A identical marrow transplants in aplastic anemia, acute leukemia, and lymphosarcoma employing cyclophosphamide
82. Cyclophosphamide and urinary bladder toxicity
83. Cytological study of the effect of cyclophosphamide on the epithelium of the urinary bladder in man
84. Cyclophosphamide hemorrhagic cystitis
85. Bladder toxicity with chronic oral cyclophosphamide therapy in nonmalignant disease
86. Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis
87. Immunosuppressive and cytotoxic therapy: Long-term complications
88. Cyclophosphamide necrosis of the bladder causing calcification, contracture and reflux: Treated by colocystoplasty
89. Urinary-bladder fibrosis and telangiectarsia associated with long-term cyclophosphamide therapy
90. Urological emergencies
91. Amelioration of cyclophosphamideinduced cystitis
92. Controlled clinical studies with an antidose against urotoxicity of oxazaphosphorines: preliminary results
93. Carcinoma of the urinary bladder in patients receiving cyclophosphamide
94. Does cyclophosphamide induce bladder cancer?
95. The incidence of bladder cancer after cyclophosphamide therapy
96. Cyclophosphamide and the bladder (letter)
97. Effect of a single dose of cyclophosphamide: V. Protective effect of diversion of the urinary stream on dog bladder
98. Gonadal dysfunction in patients receiving chemotherapy for cancer
99. Sterility and testicular atrophy related to cyclophosphamide therapy
100. Cyclophosphamide and reproductive function
101. Alkylating agents and human spermatogenesis
102. Gonadotropin response to luteinizing releasing hormone in men with germinal aplasia
103. Leydig cell dysfunction in male patients with Hodgkins disease receiving chemotherapy (abstract)
104. Cyclical combination chemotherapy and gonadal dysfunction
105. The effect of alkylating agents on the reproductive and hormonal testicular function in patients with rheumatoid arthritis
106. Reversible drug-induced sterility in a patient with acute leukemia
107. Return of fertility in a patient with cyclophosphamide-induced azoospermia
108. Amenorrhea in patients with Hodgkin's disease treated with antineoplastic agents
109. Multiple late complications of cyclophosphamide, including ovarian destruction
110. Cyclophosphamide-induced ovarian failure
111. Sterility and cyclophosphamide
112. Pregnancy outcome following cancer chemotherapy
113. Chromosome abnormalities from cyclophosphamide therapy in rheumatoid arthritis and progressive systemic sclerosis (scleroderma)
114. Congenital anomalies probably induced by cyclophosphamide
115. Fetal effects during cyclophosphamide and irradiation therapy
116. Genetic effects of cyclophosphamide, ifosfamide and trofosfamide
117. Experimental studies on the genesis of limb malformations produced in chicken embryos with nitrogen mustard
118. Zur Frage der carcinogen Wirkung von Krebs-Chemotherapeutica and chemischen Immunosuppressiva
119. Immunosuppression by cyclophosphamide in NZB x NZW mice with lupus nephritis
120. Influence of cyclophosphamide and other immunosuppressive drugs on immune disorders and neoplasia in NZB/NZW mice
121. Intracerebral lymphoma in a patient with central nervous system lupus on cyclophosphamide
122. Acute leukemia in rheumatoid arthritis treated with cytotoxic agents
123. Immunosuppressive drugs and acute leukemia (letter)
124. Acute leukemia complicating metastatic breast cancer
125. The comparative incidence of malignant disease in rheumatoid arthritics exposed to different treatment regimens
126. An association between the rheumatic diseases and the reticuloses
127. Alopecia activity of cyclophosphamide metabolites and related compounds in sheep
128. Alopecia and cytotoxic drugs (letter)
129. High dose cyclophosphamide administration in man
130. High dose cyclophosphamide therapy for malignant disease Toxicity tumor response and the effects of stored autologous marrow
131. Marrow transplantation in man following cyclophosphamide
132. Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide
133. Comparison of the cardiovascular actions of NSC-109, 724 (ifosfamide) and cyclophosphamide
134. Pathology of high dose intermittent cyclophosphamide therapy
135. Cytotoxic drug-induced pulmonary disease
136. Late onset pulmonary fibrosis and chest deformity in two children treated with cyclophosphamide
137. Effect of steroid hormone on activation of endoxan (cyclophosphamide)
138. Untersuchungen uber die Kombinierte cytostatische therapy: Der Einflub von Cyclophosphamid und Mitomycin C aufden Cortisonabbau in der Leber
139. Cyclophosphamide: Drug interactions and bone marrow transplantation
140. 144C] cyclophosphamide and its radioactive metabolites in rats pretreated with prednisolone
141. Allopurinol and cytotoxic drugs. Interaction in relation to bone marrow depression
142. Impairment of drug metabolism in man by allopurinol and nortriptyline
143. Response of a “resistant” plasmocytoma to alkylating agents and x-ray in combination with the “exercision repair inhibitors” caffeine and chloroquine
144. Release of ultraviolet light-induced thymine dimers from DNA in E. Coli K-12
145. Clinical toxicological study of cyclohexylamine salt of N, N-Bis (2-chloroethyl) phosphoradiamidic acid (NSC-69945; OMF-59)
146. Water intoxication in man after cyclophosphamide therapy: Time course and relation to drug activation
147. Cyclophosphamide hepatotoxicity in a patient with systemic lupus erythematosus
148. Massive hepatic necrosis after cyclophosphamide (letter)
149. Poor response in two cases of juvenile rheumatoid arthritis to treatment with cyclophosphamide
150. Immediate cerebral symptoms during rapid intravenous infusion of cyclophosphamide (NSC-26271)
151. Cyclophosphamide in solid tumors
152. Possible anaphylatic reaction to intravenous cyclophosphamide Report of a case
153. Generalized urticaria to cyclophosphamide. Type I hypersensitivity to an immunosuppressive agent
154. Oropharyngeal sensation associated with rapid intravenous administration of cyclophosphamide (NSC-26271)
155. Cyclophosphamideinduced nail pigmentation (letter)
156. Cyclophosphamide: Use in clinical practice
157. Immunosuppressive therapy in lupus erythematosus
158. A new therapeutic strategy in systemic vasculitis?
159. Randomized versus historical controls for clinical trials
160. Immunosuppressive drugs in rheumatoid arthritis
161. Immunosuppressive therapy of immunoinflammatory diseases
162. Comparison of azathioprine, cyclophosphamide, and gold in treatment of rheumatoid arthritis
163. A controlled trial of cyclophosphamide in rheumatoid arthritis
164. Immune response of patients with rheumatoid arthritis during cyclophosphamide treatment
165. Double-blind study of cyclophosphamide in rheumatoid arthritis
166. A double-blind comparative trial of cyclophosphamide in rheumatoid arthritis (abstract)
167. Controlled trial of cyclophosphamide in rheumatoid arthritis
168. Cyclophosphamide therapy for rheumatoid arthritis
169. A combined clinical and immunological assessment of four cyclophosphamide regimes in rheumatoid arthritis
170. Toxicity of Immunosuppressive drugs in man
171. Treatment of rheumatoid arthritis
172. Rheumatoid vasculitis: Effect of cyclophosphamide on the clinical course and levels of circulating immune complexes
173. Plasma exchange in rheumatoid vasculitis
174. Factor VIII antibodies in heumatoid arthritis: Effect of cyclophosphamide
175. Cyclophosphamide in the treatment of systemic lupus erythematosus: 7 years experience
176. Cyclophosphamide in systemic lupus erythematosus
177. Cyclophosphamide in the treatment of systemic lupus erythematosus
178. Corticosteroid therapy of the collagen vascular disorders
179. Immunosuppressive therapy in connective tissue diseases other than rheumatoid arthritis
180. Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis
181. A double-blind controlled trial comparing cyclophosphamide, azathioprine, and placebo in the treatment of lupus glomerulonephritis
182. Cyclophosphamide in lupus nephritis: A controlled trial
183. Studies in the treatment of lupus nephritis
184. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide
185. Comparisons of chlorambucil, azathioprine or cyclophosphamide in the treatment of lupus nephritis
186. Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis
187. Regimens for treatment of lupus nephritis (letter)
188. Systemic lupus erythematosus-survival patterns: Experience with 609 patients
189. A multicenter study of outcome in systemic lupus erythematosus: I entry variables as predictors of prognosis
190. A multicenter study of outcome in systemic lupus erythematosus: II causes of death
191. Hematologic aspects of systemic lupus erythematosus Current concepts
192. Pulmonary hemorrhage in systemic lupus erythematosus
193. Pulmonary hypertension in a child with mixed connective tissue disease
194. Wegener's granulomatosis: Studies in eighteen patients and a review of the literature
195. Wegener's granulomatosis: Long-term followup of patients treated cyclophosphamide
196. Treatment of Wegener's granulomatosis of lung
197. Wegener's granulomatosis, lymphomatoid granulomatosis and benign lymphocytic angiitis and granulomatosis of lung: Recognition and treatment
198. Respiratory vasulitis
199. Wegener's granulomatosis: Successful treatment with highdose cyclophosphamide
200. Lymphomatoid granulomatosis Report of a case and review of the literature
201. Lymphomatoid granulomatosis: Prospective clinical and therapeutic experience over 10 years
202. Lymphomatoid granulomatosis: Clinicopathological study of four cases and literature review
203. Cyclophosphamide therapy of severe systemic necrotizing vasculitis
204. Cyclophosphamide-induced remission in advanced polyarteritis nodosa
205. Immunosuppressive and corticosteroid therapy of polyarteritis nodosa
206. Onset of polyarteritis nodosa during allergic hyposensitization treatment
207. Clinical features, prognosis and response to treatment in polyarteritis
208. Polyarteritis nodosa, hairy cell leukemia and splenosis
209. Chronic recurrent small-vessel cutaneous vasculitis: Clinical experience in 13 patients
210. Immunosuppressive therapy in polymyositis
211. A computerassisted analysis of 153 patients with polymyositis and dermatomyositis
212. Immunosuppressive agents in corticosteroid-refractory childhood dermatonyositis
213. Dermatomyositis: observations on the use of immunosuppressive therapy and review of the literature
214. Plasmapheresis in idiopathic inflammatory myopathy: Experience with 35 patients
215. Biological and clinical significance of cryoglobulins A report of 86 cases
216. Intestinal vasculitis with essential, mixed cryoglobulinemia
217. Mixed cryoglobulinemia: Clinical aspects and long-term follow-up of 40 patients
218. The effect of combinatiom therapy (steroids, immunosuppressives, and plasmapheresis) on 5 mixed cryoglobulinemia patients with renal, neurologic, and vascular involvement
219. Behcet's disease in Japan: Ophthalmological aspects
220. Cyclophosphamide therapy of Behcet's disease
221. Use of combined plasmapheresis and immunosuppression in the treatment of Goodpasture's syndrome
222. Plasmapheresis and immunosuppressive drug therapy in scleroderma
223. Immunosuppressive therapy in steroid-resistant proliferative glomerulonephritis accompanied by nephrotic syndrome
224. Cytotoxic drugs in steroid resistant renal disease. Alkylating and antimetabolic agents in the treatment of nephrotic syndrome, lupus nephritis, chronic glomerulonephritis, and purpura nephritis in children
225. Cyclophosphamide therapy for severe juvenile rheumatoid arthritis